Home » Newsletters » BioWorld Science

BioWorld Science

April 10, 2019

View Archived Issues

BAY-218, a first-in-class AhR antagonist for overcoming tumor-mediated immunosuppression

How CMV blocks immune recognition

New bromophenol derivatives as specific PTP1B inhibitors for the treatment of type 2 diabetes

Mechanism underlying youthful and aging skin found in mice

Patient enrollment ongoing in phase I study of LYN-00101

First-in-human data for PLN-74809 support development of the candidate for the treatment of IPF

First patient enrolled in phase I/II study of NanoDoce for the treatment of bladder cancer

Enesi Pharma and Oxford Vaccine Group to develop plague vaccine

Researchers present new oncolytic adenovirus shRNA-based immunotherapy strategy

A*STAR describes new isoprenylcysteine carboxylmethyltransferase inhibitors

ImmuneOnco Biopharma reports discovery of novel bispecific antibody-trap, IMM-0306

Preclinical data presented for a novel cross-linking dependent 4-1BB agonist antibody, PE-0116

Next-generation of HBV CAMs presented

Zhejiang Hisun Pharmaceutical discloses mutant c-Kit/PDGFR-alpha inhibitors

New TLR7 agonists patented by Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical

University of Nottingham presents CDK12/cyclin K inhibitors

Protein-arginine deiminase type-4 inhibitors discovered at Jubilant Biosys

U.S. approval for Evenity for osteoporosis in postmenopausal women at high risk for fracture

European Commission approves Lynparza for germline BRCA-mutated HER-negative advanced breast cancer

Discovery and characterization of selective AMPAR/gamma-8 negative modulators as antiepileptics

Results of phase I trial of RNA-based adjuvant CV-8102 combined with a licensed rabies vaccine

DNA-encoded monoclonal antibody prevents Zika infection in mice and nonhuman primates

GHIT Fund grant supports further development of asexual blood-stage malaria vaccine candidate

Dual kappa/delta-opioid agonist CA-1001 shows efficacy in pain models

PharmaMar announces new immuno-oncology program